Resmed Q2: Mask sales surge as new products, resupply gain traction

SAN DIEGO – Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and Latin America. 

Even excluding revenue from VirtuOx, which Resmed acquired in the fourth quarter of 2025, the company still posted double-digit growth in mask revenue during the quarter, according to Chairman and CEO Mick Farrell, who discussed the results during a recent earnings call. 

New product launches fuel mask sales 

One factor driving mask growth is product innovation, including new launches such as the AirFit F30i Comfort full-face fabric mask, Farrell said. 

“Look, yes, I think when we launch a new mask, it can have some good cycles,” he said. “Our channel doesn't tend to really stock ahead of demand. They tend to buy when a new product comes, and they start to see demand and buy more. I can tell you that the new F30i Comfort – I think this is changing the basis of competition, and I think we're going to see some really good adoption of these masks over time.” 

Resmed estimates overall market growth for masks in the high single digits, putting the company ahead of broader industry trends, Farrell said. 

Resupply strategies support continued growth 

Another contributor to mask revenue growth has been resupply, Farrell said. Resmed is leveraging patient engagement tools such as its myAir app, while provider customers are increasingly using resupply solutions through Brightree to prompt users on mask maintenance and replacement. 

“So, we’re having some success with that,” he said. “You can’t do that every quarter, and you can’t drive it every quarter, but I do think we can meet and beat that high, single-digit growth of masks every quarter as we go meet and/or beat.” 

Device sales improve, while competitive bidding pressure eases 

Resmed also reported an 8% increase in device revenue in the second quarter in the U.S., a result Farrell described as a “good improvement.” With devices excluded from the next round of Medicare’s competitive bidding program (CBP), the company expects device growth to track at or above mid-single-digit market growth. 

“Now that we’re not in competitive bidding, there’s no distractions,” he said. “Let’s grow our business together.” 

Additional highlights from the earnings call 

• Resmed has signed a lease and begun construction on a new U.S. distribution center in Indiana, which it expects to be operational during calendar year 2027. 
• The company also now has three years of data on patients who have been prescribed both a GLP-1 medication and a CPAP device. According to its findings, patients with a combined prescription are 3% more likely to experience a resupply event at one year and 6% more likely at three years. 
• Resmed’s continuing medical education (CME) program for clinicians has now been completed nearly 60,000 times, representing a 50% increase compared to the first quarter.